|
Report Date : |
08.11.2012 |
IDENTIFICATION DETAILS
|
Name : |
EIMC UNITED PHARMACEUTICALS SAE |
|
|
|
|
Registered Office : |
|
|
|
|
|
Country : |
|
|
|
|
|
Year of Establishment : |
2003 |
|
|
|
|
Com. Reg. No.: |
3220, Cairo |
|
|
|
|
Legal Form : |
Egyptian Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacturers of human and veterinary pharmaceutical
preparations |
|
|
|
|
No. of Employees : |
250 employees |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – June 30th, 2012
|
Country Name |
Previous Rating (31.03.2012) |
Current Rating (30.06.2012) |
|
Egypt |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Egypt - ECONOMIC OVERVIEW
Occupying the northeast corner of the African continent, Egypt is bisected by the highly fertile Nile valley, where most economic activity takes place. Egypt's economy was highly centralized during the rule of former President Gamal Abdel NASSER but opened up considerably under former Presidents Anwar EL-SADAT and Mohamed Hosni MUBARAK. Cairo from 2004 to 2008 aggressively pursued economic reforms to attract foreign investment and facilitate GDP growth. Despite the relatively high levels of economic growth in recent years, living conditions for the average Egyptian remained poor and contributed to public discontent. After unrest erupted in January 2011, the Egyptian Government drastically increased social spending to address public dissatisfaction, but political uncertainty at the same time caused economic growth to slow significantly, reducing the government's revenues. Tourism, manufacturing, and construction are among the hardest hit sectors of the Egyptian economy, and economic growth is likely to remain slow at least through 2012. The government is utilizing foreign exchange reserves to support the Egyptian pound and Egypt may seek a loan from the International Monetary Fund.
|
Source : CIA |
Company Name : EIMC UNITED PHARMACEUTICALS SAE
Country of Origin : Egypt
Legal Form : Egyptian Joint Stock Company
Registration Date : 2003
Commercial Registration Number : 3220, Cairo
Issued Capital : £E 80,000,000
Paid up Capital : £E 80,000,000
Total Workforce : 250
Activities : Manufacturers of human and veterinary pharmaceutical preparations.
Financial Condition : Undetermined
Payments : Nothing detrimental uncovered
EIMC UNITED
PHARMACEUTICALS SAE
Registered &
Physical Address
Building : Pharma Plaza Building
Street : Asmaa Fahmy Street
Area : Nasr City
Town : Cairo
Country : Egypt
Telephone : (20-2) 22911494 / 24184011 / 22911406
Facsimile : (20-2) 24180772 / 22911525 /
24144932
Email : info@eimc.com.eg
Premises
Subject operates
from a large suite of offices that are rented and located in the Central
Business Area of Cairo.
Branch Office (s)
Location Description
·
Plot
No. 10D WA 11D Factory
premises
Industrial Zone Centre
Badr City
Helwan
·
23 El
Azhar Street Office
premises
Haram
Giza
Cairo
Tel: (20-2) 37467040
Fax: (20-2) 33846430
·
12 El
Mahdy Street Office
premises
Alexandria
Tel: (20-3) 5595050
Fax: (20-3) 5575724
·
10 Dr
Shafiq Yonis Street Office
premises
Mansoura
Tel: (20-50) 2528020
Fax: (20-50) 2528108
·
Menia Office
premises
Tel: (20-86) 2296594
Fax: (20-86) 2296594
·
20
Hashem Bakr Abu Hegy Street Office
premises
Sohag
Tel: (20-93) 2313494
Fax: (20-93) 2310472
Name Position
·
Dr Awad
Gabr Awad Khalil Chairman
·
Mohamed
El Sayed Ahmed Mohamed Managing
Director
·
Moustafa
Ali Abd El Rahman El Salamouny Director
·
Ahmed
Ali Ahmed El Fardan Director
·
Amin
Ali Hassan Mahgoul Director
·
Fouad
Shawky Finance
Manager
Date of Establishment : 2003
Legal Form :
Egyptian Joint Stock
Company
Commercial Reg. No. : 3220, Cairo
Issued Capital : £E 80,000,000
Paid up Capital : £E 80,000,000
Name of Shareholder
(s) Percentage
·
Egyptian
International Medical Centre 40%
·
Korea
United Pharma 8%
South Korea
·
Ahmed
Ali Ahmed El Fardan 5%
·
Hassan
Ahmed Mohamed Farhana 5%
·
Mohamed
Akif 3%
·
Dr Awad
Gabr Awad Khalil 2%
·
Mohamed
El Sayed Ahmed Mohamed 2%
·
Dok
Young King Pharma 2%
South Korea
·
Amin
Ali Hassan Mahgoul 1%
·
Local
businessmen and private investors 32%
Activities: Engaged in the manufacture of human and veterinary
pharmaceutical preparations.
Production
Capacity: 30 million
packages per year.
Import
Countries: Europe and GCC
countries.
Subject has a
workforce of approximately 250 employees.
Companies
registered in Egypt are not legally required to make their accounts public and
no financial information was released by the company or submitted by outside
sources.
·
Misr
International Bank (MIBANK)
PO Box: 631
Cairo
Tel: (20-2) 25931002
Fax: (20-2) 25912306
No complaints
regarding subject’s payments have been reported.
Local sources report that payment obligations are met in a generally timely manner and the operating history is clear. As such the company is deemed a fair trade risk.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.54.25 |
|
UK Pound |
1 |
Rs.87.00 |
|
Euro |
1 |
Rs.69.83 |
INFORMATION DETAILS
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.